Bliss GVS Pharma Limited has informed the Exchange regarding Appointment of Mr Narsimha Shibroor Kamath as Managing Director & CEO of the company w.e.f. December 23, 2025.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bliss GVS Pharma Limited has informed the stock exchange about the appointment of Mr Narsimha Shibroor Kamath as the new Managing Director and CEO of the company. The appointment will take effect from December 23, 2025. This is a senior leadership change at the top of the pharma company, with the new MD & CEO set to lead its operations and strategy going forward. The disclosure has been made to the NSE as a regulatory filing under corporate governance norms.
A new MD & CEO appointment marks a key leadership transition that could shape the company's strategic direction. Shareholders will watch for the new leader's background, experience, and any early signals on business priorities or performance outlook.